<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2018-60-69</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2501</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОГРАММА НЕПРЕРЫВНОГО ПОСЛЕДИПЛОМНОГО ОБРАЗОВАНИЯ ВРАЧЕЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>POSTGRADUATE PROGRAM OF CONTINUING MEDICAL EDUCATION</subject></subj-group></article-categories><title-group><article-title>Псориатический артрит: классификация, клиническая картина, диагностика, лечение</article-title><trans-title-group xml:lang="en"><trans-title>PSORIATIC ARTHRITIS: CLASSIFICATION, CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коротаева</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Korotaev</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> заведующая лабораторией диагностики и инновационных методов лечения псориатического артрита, доктор медицинских наук. </p><p>Москва.</p></bio><bio xml:lang="en"><p>Moscow.</p></bio><email xlink:type="simple">tatianakorotaeva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корсакова</surname><given-names>Ю. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Korsakova</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>тарший научный сотрудник лаборатории диагностики и инновационных методов лечения псориатического артрита, кандидат медицинских наук.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Moscow.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научноисследовательский институт ревматологии им. В.А.Насоновой».</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A.Nasonova Research Institute of Rheumatology.</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>03</day><month>03</month><year>2018</year></pub-date><volume>56</volume><issue>1</issue><fpage>60</fpage><lpage>69</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Коротаева Т.В., Корсакова Ю.Л., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Коротаева Т.В., Корсакова Ю.Л.</copyright-holder><copyright-holder xml:lang="en">Korotaev T.V., Korsakova Y.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2501">https://rsp.mediar-press.net/rsp/article/view/2501</self-uri><abstract><p>Псориатический артрит (ПсА) – хроническое воспалительное заболевание суставов, позвоночника и энтезисов из группы спондилоартритов (СпА), которое обычно наблюдается у больных псориазом (Пс). Диагноз ПсА устанавливается с помощью критериев псориатического артрита (CASPAR). Заболевание является результатом взаимодействий между генетическими, иммунологическими факторами и факторами внешней среды. К основным клиническим проявлениям ПсА относят: периферический артрит, энтезит, дактилит, спондилит. ПсА необходимо дифференцировать с ревматоидным артритом, подагрой, реактивным артритом, остеоартритом, анкилозирующим спондилитом. В связи с тем что ПсА является клинически гетерогенным заболеванием, оценка его активности осуществляется с помощью комплексных индексов, с учетом наличия у больного артрита, энтезита, дактилита, спондилита. Целью лечения ПсА является достижение ремиссии или минимальной активности основных клинических проявлений заболевания, замедление или предупреждение рентгенологического прогрессирования, увеличение продолжительности и качества жизни пациентов, а также снижение риска коморбидных заболеваний, что достигается с помощью широкого спектра препаратов различных классов. Терапию следует выбирать с учетом клинических проявлений ПсА и коморбидных состояний пациентов.</p></abstract><trans-abstract xml:lang="en"><p>soriatic arthritis (PsA) is a chronic inflammatory disease of the joints, spine and entheses from a group of spondyloarthritis (SpA), which is usually observed in patients with psoriasis (Ps). The diagnosis of PsA is based on the CASPAR criteria for psoriatic arthritis. The disease results from interactions between genetic, immunological and environmental factors. The main clinical manifestations of PsA include peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA must be differentiated from rheumatoid arthritis, gout, reactive arthritis, osteoarthritis, and ankylosing spondylitis. Due to the fact that PsA is a clinically heterogeneous disease, its activity is assessed using complex indices, by taking into account that the patient has arthritis, enthesitis, dactylitis, and spondylitis. The goal of treatment for PsA is to achieve remission or minimal activity of the main clinical manifestations of the disease, to slow down or prevent radiographic progression, to increase life expectancy and quality of life in the patients, and to reduce the risk of comorbidities, which is achieved through a wide range of drugs of different classes. Therapy should be chosen based on the clinical manifestations of PsA and comorbidities in the patients. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>: псориаз</kwd><kwd>псориатический артрит</kwd><kwd>лечение</kwd><kwd>оценка активности и эффективности терапии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>psoriatic arthritis</kwd><kwd>treatment</kwd><kwd>evaluation of activity and effectiveness of therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809-12.</mixed-citation><mixed-citation xml:lang="en">Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809-12.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778-83. doi: 10.1093/rheumatology/keg217</mixed-citation><mixed-citation xml:lang="en">McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778-83. doi: 10.1093/rheumatology/keg217</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55-78. doi: 10.1016/0049-0172(73)90035-8</mixed-citation><mixed-citation xml:lang="en">Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55-78. doi: 10.1016/0049-0172(73)90035-8</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zias J, Mitchell P. Psoriatic arthritis in a fifth-century Judean Desert monastery. Am J Phys Anthropol. 1996;101:491-502. doi: 10.1002/(SICI)1096-8644(199612)101:4&lt;491::AIDAJPA4&gt;3.0.CO;2-Z</mixed-citation><mixed-citation xml:lang="en">Zias J, Mitchell P. Psoriatic arthritis in a fifth-century Judean Desert monastery. Am J Phys Anthropol. 1996;101:491-502. doi: 10.1002/(SICI)1096-8644(199612)101:4&lt;491::AIDAJPA4&gt;3.0.CO;2-Z</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore). 1974;53:343-64. doi: 10.1097/00005792-19740900000002</mixed-citation><mixed-citation xml:lang="en">Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore). 1974;53:343-64. doi: 10.1097/00005792-19740900000002</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563-74. doi: 10.1056/NEJMra1406182</mixed-citation><mixed-citation xml:lang="en">Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563-74. doi: 10.1056/NEJMra1406182</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor WJ, Gladman DD, Helliwell PS, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73. doi: 10.1002/art.21972</mixed-citation><mixed-citation xml:lang="en">Taylor WJ, Gladman DD, Helliwell PS, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73. doi: 10.1002/art.21972</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Olivieri I, Padula A, D’Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. J Rheumatol. 2009; Suppl 83:28-9. doi: 10.3899/jrheum.090218</mixed-citation><mixed-citation xml:lang="en">Olivieri I, Padula A, D’Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. J Rheumatol. 2009; Suppl 83:28-9. doi: 10.3899/jrheum.090218</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheum. 2016;68:915-23. doi: 10.1002/art.39494</mixed-citation><mixed-citation xml:lang="en">Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheum. 2016;68:915-23. doi: 10.1002/art.39494</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:242-8. doi: 10.1016/j.jaad.2015.05.001</mixed-citation><mixed-citation xml:lang="en">Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:242-8. doi: 10.1016/j.jaad.2015.05.001</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Чамурлиева МН, Логинова ЕЮ, Коротаева ТВ. Выявляемость псориатического артрита у больных псориазом в дерматологической и ревматологической клинике. Современная ревматология. 2016;10(4):47-50 [Chamurlieva MN, Loginova EYu, Korotaeva TV. Detection rates of psoriatic arthritis in patients with psoriasis in a dermatology and rheumatology clinic. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):47-50 (In Russ.)]. doi: 10.14412/1996-7012-2016-4-47-50</mixed-citation><mixed-citation xml:lang="en">Чамурлиева МН, Логинова ЕЮ, Коротаева ТВ. Выявляемость псориатического артрита у больных псориазом в дерматологической и ревматологической клинике. Современная ревматология. 2016;10(4):47-50 [Chamurlieva MN, Loginova EYu, Korotaeva TV. Detection rates of psoriatic arthritis in patients with psoriasis in a dermatology and rheumatology clinic. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):47-50 (In Russ.)]. doi: 10.14412/1996-7012-2016-4-47-50</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015;10(4):e0123582. doi: 10.1371/journal.pone.0123582</mixed-citation><mixed-citation xml:lang="en">Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015;10(4):e0123582. doi: 10.1371/journal.pone.0123582</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken). 2012;64:1593-601. doi: 10.1002/acr.21725</mixed-citation><mixed-citation xml:lang="en">Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken). 2012;64:1593-601. doi: 10.1002/acr.21725</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tillett W, Shaddick G, Askari A, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology (Oxford). 2015;54:157-62. doi: 10.1093/rheumatology/keu264</mixed-citation><mixed-citation xml:lang="en">Tillett W, Shaddick G, Askari A, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology (Oxford). 2015;54:157-62. doi: 10.1093/rheumatology/keu264</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Arumugam R, McHugh NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol. 2012;89 Suppl:32-5. doi: 10.3899/jrheum.120239</mixed-citation><mixed-citation xml:lang="en">Arumugam R, McHugh NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol. 2012;89 Suppl:32-5. doi: 10.3899/jrheum.120239</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis – a singlecenter study from the UK. J Rheumatol. 2010;37:2141-4. doi: 10.3899/jrheum.100034</mixed-citation><mixed-citation xml:lang="en">Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis – a singlecenter study from the UK. J Rheumatol. 2010;37:2141-4. doi: 10.3899/jrheum.100034</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376:957-70. doi: 10.1056/NEJMra1505557</mixed-citation><mixed-citation xml:lang="en">Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376:957-70. doi: 10.1056/NEJMra1505557</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mease PJ. Psoriatic Arthritis: update on pathophysiology, assessement and management. Ann Rheum Dis. 2011;70 Suppl:77-84. doi: 10.1136/ard.2010.140582</mixed-citation><mixed-citation xml:lang="en">Mease PJ. Psoriatic Arthritis: update on pathophysiology, assessement and management. Ann Rheum Dis. 2011;70 Suppl:77-84. doi: 10.1136/ard.2010.140582</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71:1273-7. doi: 10.1136/annrheumdis-2012-201299</mixed-citation><mixed-citation xml:lang="en">Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71:1273-7. doi: 10.1136/annrheumdis-2012-201299</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Коротаева ТВ. Псориатический артрит: клиника, диагностика, патогенез, лечение, маркеры кардиоваскулярного риска. Москва: НПО «Медиа-Графика»; 2013. 309 с. [Korotaeva TV. Psoriaticheskii artrit: klinika, diagnostika, patogenez, lechenie, markery kardiovaskulyarnogo riska [Psoriatic arthritis: clinic, diagnosis, pathogenesis, treatment, markers of cardiovascular risk]. Moscow: NPO «Media-Grafika»; 2013. 309 p.]. ISBN 978-5-905541-02-5.</mixed-citation><mixed-citation xml:lang="en">Коротаева ТВ. Псориатический артрит: клиника, диагностика, патогенез, лечение, маркеры кардиоваскулярного риска. Москва: НПО «Медиа-Графика»; 2013. 309 с. [Korotaeva TV. Psoriaticheskii artrit: klinika, diagnostika, patogenez, lechenie, markery kardiovaskulyarnogo riska [Psoriatic arthritis: clinic, diagnosis, pathogenesis, treatment, markers of cardiovascular risk]. Moscow: NPO «Media-Grafika»; 2013. 309 p.]. ISBN 978-5-905541-02-5.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Khan M, Schentag C, Gladman DD. Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol. 2003;30:1022-6.</mixed-citation><mixed-citation xml:lang="en">Khan M, Schentag C, Gladman DD. Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol. 2003;30:1022-6.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40:1357-9. doi: 10.3899/jrheum.130163</mixed-citation><mixed-citation xml:lang="en">Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40:1357-9. doi: 10.3899/jrheum.130163</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:188-90. doi: 10.1136/ard.2003.018184</mixed-citation><mixed-citation xml:lang="en">Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:188-90. doi: 10.1136/ard.2003.018184</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kehl AS, Corr M, Weisman MH. Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheum. 2016;68:312-22. doi: 10.1002/art.39458</mixed-citation><mixed-citation xml:lang="en">Kehl AS, Corr M, Weisman MH. Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheum. 2016;68:312-22. doi: 10.1002/art.39458</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54:3564-72. doi: 10.1002/art.22173</mixed-citation><mixed-citation xml:lang="en">Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54:3564-72. doi: 10.1002/art.22173</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Colbert RA. Classification of juvenile spondyloarthritis: enthesitisrelated arthritis and beyond. Nat Rev Rheumatol. 2010;6:477-85. doi: 10.1038/nrrheum.2010.103</mixed-citation><mixed-citation xml:lang="en">Colbert RA. Classification of juvenile spondyloarthritis: enthesitisrelated arthritis and beyond. Nat Rev Rheumatol. 2010;6:477-85. doi: 10.1038/nrrheum.2010.103</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:14-7. doi: 10.1136/ard.2004.032482</mixed-citation><mixed-citation xml:lang="en">Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:14-7. doi: 10.1136/ard.2004.032482</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Chandran V, Barrett J, Schentag NC, et al. Axial Psoriatic Arthritis: update on a longterm prospective study. J Rheumatol. 2009;36;2744-50. doi: 10.3899/jrheum.090412</mixed-citation><mixed-citation xml:lang="en">Chandran V, Barrett J, Schentag NC, et al. Axial Psoriatic Arthritis: update on a longterm prospective study. J Rheumatol. 2009;36;2744-50. doi: 10.3899/jrheum.090412</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis. 2009;68:784-8. doi: 10.1136/ard.2008.101501</mixed-citation><mixed-citation xml:lang="en">Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis. 2009;68:784-8. doi: 10.1136/ard.2008.101501</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am. 2005;31(4):641-57. doi: 10.1016/j.rdc.2005.07.009</mixed-citation><mixed-citation xml:lang="en">Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am. 2005;31(4):641-57. doi: 10.1016/j.rdc.2005.07.009</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg. 2005;24:46-51. doi: 10.1016/j.sder.2005.01.006</mixed-citation><mixed-citation xml:lang="en">Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg. 2005;24:46-51. doi: 10.1016/j.sder.2005.01.006</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:31-5. doi: 10.1111/j.1468-3083.2009.03565.x</mixed-citation><mixed-citation xml:lang="en">Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:31-5. doi: 10.1111/j.1468-3083.2009.03565.x</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Gottlieb A, Korman N, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64. doi: 10.1016/j.jaad.2008.02.040</mixed-citation><mixed-citation xml:lang="en">Gottlieb A, Korman N, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64. doi: 10.1016/j.jaad.2008.02.040</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum. 2009;38:320-35. doi: 10.1016/j.semarthrit.2008.01.003</mixed-citation><mixed-citation xml:lang="en">Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum. 2009;38:320-35. doi: 10.1016/j.semarthrit.2008.01.003</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8:331-4. doi: 10.1089/met.2009.0124</mixed-citation><mixed-citation xml:lang="en">Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8:331-4. doi: 10.1089/met.2009.0124</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Li W-Q, Han J-L, Chan TA. Psoriasis and psoriatic arthritis and increased risk of incedent Crohn's disease in US women. Ann Rheum Dis. 2013 Jul;72(7):1200-5. doi: 10.1136/annrheumdis2012-202143</mixed-citation><mixed-citation xml:lang="en">Li W-Q, Han J-L, Chan TA. Psoriasis and psoriatic arthritis and increased risk of incedent Crohn's disease in US women. Ann Rheum Dis. 2013 Jul;72(7):1200-5. doi: 10.1136/annrheumdis2012-202143</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27:118-26. doi: 10.1097/BOR.0000000000000152</mixed-citation><mixed-citation xml:lang="en">Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27:118-26. doi: 10.1097/BOR.0000000000000152</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Gossec L, Smolen J, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350</mixed-citation><mixed-citation xml:lang="en">Gossec L, Smolen J, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Mease PJ. Assessment tools in psoriatic arthritis. J Rheumatol. 2008;35:1426-30.</mixed-citation><mixed-citation xml:lang="en">Mease PJ. Assessment tools in psoriatic arthritis. J Rheumatol. 2008;35:1426-30.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise – the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007;34:1740-5.</mixed-citation><mixed-citation xml:lang="en">Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise – the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007;34:1740-5.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis. 2010;69:546-9. doi: 10.1136/ard.2009.117945</mixed-citation><mixed-citation xml:lang="en">Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis. 2010;69:546-9. doi: 10.1136/ard.2009.117945</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42(2):244-57. doi: 10.1093/rheumatology/keg072</mixed-citation><mixed-citation xml:lang="en">Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42(2):244-57. doi: 10.1093/rheumatology/keg072</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387-94. doi: 10.1136/ard.2008.094946</mixed-citation><mixed-citation xml:lang="en">Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387-94. doi: 10.1136/ard.2008.094946</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2010;70:272-7. doi: 10.1136/ard.2010.129379</mixed-citation><mixed-citation xml:lang="en">Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2010;70:272-7. doi: 10.1136/ard.2010.129379</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Helliwell PS, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:98691. doi: 10.1136/annrheumdis-2012-201341</mixed-citation><mixed-citation xml:lang="en">Helliwell PS, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:98691. doi: 10.1136/annrheumdis-2012-201341</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther. 2010;12(3):94-8. doi: 10.1186/ar3021</mixed-citation><mixed-citation xml:lang="en">Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther. 2010;12(3):94-8. doi: 10.1186/ar3021</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62:965-9. doi: 10.1002/acr.20155</mixed-citation><mixed-citation xml:lang="en">Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62:965-9. doi: 10.1002/acr.20155</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33:1417-21.</mixed-citation><mixed-citation xml:lang="en">Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33:1417-21.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum. 2016;68:1060-71. doi: 10.1002/art.39573</mixed-citation><mixed-citation xml:lang="en">Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum. 2016;68:1060-71. doi: 10.1002/art.39573</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510. doi: 10.1136/annrheumdis2015-208337</mixed-citation><mixed-citation xml:lang="en">Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510. doi: 10.1136/annrheumdis2015-208337</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64 Suppl 2:ii74-ii77. doi: 10.1136/ard.2004.030783</mixed-citation><mixed-citation xml:lang="en">Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64 Suppl 2:ii74-ii77. doi: 10.1136/ard.2004.030783</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368-77. doi: 10.1093/rheumatology/kes001</mixed-citation><mixed-citation xml:lang="en">Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368-77. doi: 10.1093/rheumatology/kes001</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939-50. doi: 10.1002/art.20253</mixed-citation><mixed-citation xml:lang="en">Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939-50. doi: 10.1002/art.20253</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:723-38. doi: 10.1016/j.rdc.2015.07.010</mixed-citation><mixed-citation xml:lang="en">Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:723-38. doi: 10.1016/j.rdc.2015.07.010</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Weitz JE, Ritchlin CT. Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opin Biol Ther. 2014;14:515-26. doi: 10.1517/14712598.2014.890587</mixed-citation><mixed-citation xml:lang="en">Weitz JE, Ritchlin CT. Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opin Biol Ther. 2014;14:515-26. doi: 10.1517/14712598.2014.890587</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-ofconcept trial. Ann Rheum Dis. 2014;73:349-56. doi: 10.1136/annrheumdis-2012-202646</mixed-citation><mixed-citation xml:lang="en">McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-ofconcept trial. Ann Rheum Dis. 2014;73:349-56. doi: 10.1136/annrheumdis-2012-202646</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79-87. doi: 10.1136/annrheumdis-2016-209709</mixed-citation><mixed-citation xml:lang="en">Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79-87. doi: 10.1136/annrheumdis-2016-209709</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. doi: 10.1136/annrheumdis-2013205056</mixed-citation><mixed-citation xml:lang="en">Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. doi: 10.1136/annrheumdis-2013205056</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a sixmonth, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176</mixed-citation><mixed-citation xml:lang="en">Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a sixmonth, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
